Portal de Periódicos da CAPES

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

2015; Nature Portfolio; Volume: 15; Issue: 11 Linguagem: Inglês

10.1038/nrc4019

1474-1768

David D.L. Bowtell, Steffen Böhm, Ahmed A. Ahmed, Paul-Joseph Aspuria, Robert C. Bast, Valerie Beral, Jonathan S. Berek, Michael J. Birrer, Sarah P. Blagden, Michael A. Bookman, James D. Brenton, Katherine B. Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Richard J. Edmondson, Christina Fotopoulou, Hani Gabra, Jérôme Galon, Charlie Gourley, Valerie Heong, David G. Huntsman, Marcin P. Iwanicki, Beth Y. Karlan, Allyson Kaye, Ernst Lengyel, Douglas A. Levine, Karen H. Lu, Iain A. McNeish, Usha Menon, Steven A. Narod, Brad H. Nelson, Kenneth P. Nephew, Paul D.P. Pharoah, Daniel J. Powell, Pilar Ramos, Iris L. Romero, Clare L. Scott, Anil K. Sood, Euan A. Stronach, Frances R. Balkwill,

PARP inhibition in cancer therapy

This Opinion article outlines a set of research priorities, based on discussions held at the 2015 Helene Harris Memorial Trust Ovarian Cancer Action meeting, that the authors believe will reduce incidence and improve outcomes for women with high-grade serous ovarian cancer. High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.